Bendamustine Injection

About Bendamustine Injection

 Bendamustine Injection:-

Bendit (Generic Treanda) is a rationally designed purine analog and alkylator hybrid. It damages the DNA in cancer cells, which leads to the normal path of cell death (apoptosis). It also stops cancer cells from dividing to create new cancer cells.

Bendit (Generic Treanda) is specifically indicated for: 1) the treatment of chronic lymphocytic leukemia where efficacy relative to first line therapies other than chlorambucil has not been established, and 2) indolent B-cell non-Hodgkins lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Bendit (Generic Treanda) is supplied as a powder in a 100 mg vial to be reconstituted with sterile water for intravenous administration.

The recommended initial dose of the drug for the treatment of non-Hodgkin's lymphoma is 120 mg/m2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles. Bendit (Generic Treanda) administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant > Grade 2 non-hematologic toxicity.
Dose modifications for hematologic toxicity: reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle. If Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.
Dose modifications for non-hematologic toxicity: reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle. If Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.

The recommended initial dose of the drug for the treatment of chronic lymphocytic leukemia is 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Bendit (Generic Treanda) administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant >Grade 2 non-hematologic toxicity.
Dose modifications for hematologic toxicity: reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on Days 1 and 2 of each cycle.

Indications and Dosage

Bendamustine Injection is designed for use in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. The specific dosage and administration schedule should be determined by a healthcare professional based on the patients clinical condition and established guidelines. Always adhere strictly to prescribed instructions.


Preparation and Administration

Before administration, the lyophilized powder must be reconstituted with sterile water for injection, then further diluted with 0.9% sodium chloride solution. Administration is by intravenous infusion only. The preparation must be handled under aseptic conditions and used immediately post-reconstitution to ensure sterility, as the vial does not contain preservatives.


Safety and Monitoring

This medication should only be used under the supervision of qualified medical personnel. Blood counts and liver function must be closely monitored throughout the treatment due to potential myelosuppression and hepatic effects. Patients with known hypersensitivity to Bendamustine or its excipients must not use this product.